SIRT1 inhibition restores apoptotic sensitivity in p53-mutated human keratinocytes

Toxicology and Applied Pharmacology

Volumn 277, Issue 3, 2014, Pages 288-297

  Herbert, Katharine J ^a   Cook, Anthony L ^a   Snow, Elizabeth T ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Keratinocytes; MiR 34a; P53; SIRT1

Indexed keywords

CAMPTOTHECIN; MICRORNA 34A; PROTEIN BCL 2; PROTEIN P53; SIRTUIN 1;

APOPTOSIS; ARTICLE; CELL DEATH; CELL LINE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DNA DEGRADATION; FEEDBACK SYSTEM; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; KERATINOCYTE; PROTEIN EXPRESSION; SKIN CANCER;

KERATINOCYTES; MIR-34A; P53; SIRT1;

APOPTOSIS; CELL LINE; GENE EXPRESSION REGULATION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; KERATINOCYTES; MICRORNAS; MUTATION; OLIGONUCLEOTIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; SIRTUIN 1; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899943311     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2014.04.001     Document Type: Article

References (71)

1. Aranha M.M., Santos D.M., Sola S., Steer C.J., Rodrigues C.M. miR-34a regulates mouse neural stem cell differentiation. PLoS One 2011, 6:e21396.
2. Beneke R., Geisen C., Zevnik B., Bauch T., Muller W.U., Kupper J.H., Moroy T. DNA excision repair and DNA damage-induced apoptosis are linked to poly(ADP-ribosyl)ation but have different requirements for p53. Mol. Cell. Biol. 2000, 20:6695-6703.
3. Bommer G.T., Gerin I., Feng Y., Kaczorowski A.J., Kuick R., Love R.E., Zhai Y., Giordano T.J., Qin Z.S., Moore B.B., MacDougald O.A., Cho K.R., Fearon E.R. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr. Biol. 2007, 17:1298-1307.
4. Brown C.J., Lain S., Verma C.S., Fersht A.R., Lane D.P. Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 2009, 9:862-873.
5. Cabelguenne A., Blons H., de Waziers I., Carnot F., Houllier A.M., Soussi T., Brasnu D., Beaune P., Laccourreye O., Laurent-Puig P. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J. Clin. Oncol. 2000, 18:1465-1473.
6. Chan W.M., Siu W.Y., Lau A., Poon R.Y. How many mutant p53 molecules are needed to inactivate a tetramer?. Mol. Cell. Biol. 2004, 24:3536-3551.
7. Chang J., Davis-Dusenbery B.N., Kashima R., Jiang X., Marathe N., Sessa R., Louie J., Gu W., Lagna G., Hata A. Acetylation of p53 stimulates miRNA processing and determines cell survival following genotoxic stress. EMBO J. 2013, 32:3192-3205.
8. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., Wojcik S.E., Aqeilan R.I., Zupo S., Dono M., Rassenti L., Alder H., Volinia S., Liu C.-g., Kipps T.J., Negrini M., Croce C.M. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:13944-13949.
9. Concepcion C.P., Han Y.-C., Mu P., Bonetti C., Yao E., D'Andrea A., Vidigal J.A., Maughan W.P., Ogrodowski P., Ventura A. Intact p53-dependent responses in miR-34-deficient mice. PLoS Genet. 2012, 8:e1002797.
10. Desilet N., Campbell T.N., Choy F.Y. p53-based anti-cancer therapies: an empty promise?. Curr. Issues Mol. Biol. 2010, 12:143-146.
11. Dickinson M., Johnstone R.W., Prince H.M. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest. New Drugs 2010, 28(Suppl. 1):S3-S20.
12. Fabbri M., Bottoni A., Shimizu M., Spizzo R., Nicoloso M.S., Rossi S., Barbarotto E., Cimmino A., Adair B., Wojcik S.E., Valeri N., Calore F., Sampath D., Fanini F., Vannini I., Musuraca G., Dell'Aquila M., Alder H., Davuluri R.V., Rassenti L.Z., Negrini M., Nakamura T., Amadori D., Kay N.E., Rai K.R., Keating M.J., Kipps T.J., Calin G.A., Croce C.M. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 2011, 305:59-67.
13. Fang Y., Nicholl M.B. Sirtuin 1 in malignant transformation: friend or foe?. Cancer Lett. 2011, 306:10-14.
14. Fischer U., Janicke R.U., Schulze-Osthoff K. Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ. 2003, 10:76-100.
15. Gaglia G., Guan Y., Shah J.V., Lahav G. Activation and control of p53 tetramerization in individual living cells. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:15497-15501.
16. Garcia-Carbonero R., Supko J.G. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin. Cancer Res. 2002, 8:641-661.
17. Goh A.M., Coffill C.R., Lane D.P. The role of mutant p53 in human cancer. J. Pathol. 2011, 223:116-126.
18. Haigis M.C., Sinclair D.A. Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol. 2010, 5:253-295.
19. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
20. He L., He X., Lowe S.W., Hannon G.J. microRNAs join the p53 network-another piece in the tumour-suppression puzzle. Nat. Rev. Cancer 2007, 7:819-822.
21. Herbert K.J., Cook A.L., Snow E.T. SIRT1 modulates miRNA processing defects in p53-mutated human keratinocytes. J. Dermatol. Sci. 2014, 74:142-149.
22. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010, 17:193-199.
23. Hermeking H. MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat. Rev. Cancer 2012, 12:613-626.
24. Hida Y., Kubo Y., Murao K., Arase S. Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch. Dermatol. Res. 2007, 299:103-106.
25. Hoe K.K., Verma C.S., Lane D.P. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat. Rev. Drug Discov. 2014, 13:217-236.
26. Hong B., Prabhu V.V., Zhang S., van den Heuvel A.P., Dicker D.T., Kopelovich L., El-Deiry W.S. Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53. Cancer Res. 2014, 74:1153-1165.
27. Iorio M.V., Croce C.M. microRNA involvement in human cancer. Carcinogenesis 2012, 33:1126-1133.
28. Ito T., Yagi S., Yamakuchi M. MicroRNA-34a regulation of endothelial senescence. Biochem. Biophys. Res. Commun. 2010, 398:735-740.
29. Jansson M.D., Lund A.H. MicroRNA and cancer. Mol. Oncol. 2012, 6:590-610.
30. Kaufmann S.H., Desnoyers S., Ottaviano Y., Davidson N.E., Poirier G.G. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 1993, 53:3976-3985.
31. Kim M.J., Hong K.S., Kim H.B., Lee S.H., Bae J.H., Kim D.W., Dao T.T., Oh W.K., Kang C.D., Kim S.H. Ku70 acetylation and modulation of c-Myc/ATF4/CHOP signaling axis by SIRT1 inhibition lead to sensitization of HepG2 cells to TRAIL through induction of DR5 and down-regulation of c-FLIP. Int. J. Biochem. Cell Biol. 2013, 45:711-723.
32. Kwon Y.W., Kwon K.S., Moon H.E., Park J.A., Choi K.S., Kim Y.S., Jang H.S., Oh C.K., Lee Y.M., Kwon Y.G., Lee Y.S., Kim K.W. Insulin-like growth factor-II regulates the expression of vascular endothelial growth factor by the human keratinocyte cell line HaCaT. J. Invest. Dermatol. 2004, 123:152-158.
33. Lehman T.A., Modali R., Boukamp P., Stanek J., Bennett W.P., Welsh J.A., Metcalf R.A., Stampfer M.R., Fusenig N., Rogan E.M., et al. p53 mutations in human immortalized epithelial cell lines. Carcinogenesis 1993, 14:833-839.
34. Li Y., Prives C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?. Oncogene 2007, 26:2220-2225.
35. Lujambio A., Lowe S.W. The microcosmos of cancer. Nature 2012, 482:347-355.
36. Luo X., Kraus W.L. On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev. 2012, 26:417-432.
37. Luo J., Nikolaev A.Y., Imai S., Chen D., Su F., Shiloh A., Guarente L., Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001, 107:137-148.
38. Lynch C.J., Milner J. Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: a basis for p53 haplo-insufficiency. Oncogene 2006, 25:3463-3470.
39. Martynova E., Pozzi S., Basile V., Dolfini D., Zambelli F., Imbriano C., Pavesi G., Mantovani R. Gain-of-function p53 mutants have widespread genomic locations partially overlapping with p63. Oncotarget 2012, 3:132-143.
40. Olive K.P., Tuveson D.A., Ruhe Z.C., Yin B., Willis N.A., Bronson R.T., Crowley D., Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004, 119:847-860.
41. Olivier M., Hollstein M., Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol. 2010, 2:a001008.
42. Oren M., Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb. Perspect. Biol. 2010, 2:a001107.
43. Rajamohan S.B., Pillai V.B., Gupta M., Sundaresan N.R., Birukov K.G., Samant S., Hottiger M.O., Gupta M.P. SIRT1 promotes cell survival under stress by deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1. Mol. Cell. Biol. 2009, 29:4116-4129.
44. Rangel L.P., Costa D.C., Vieira T.C., Silva J.L. The aggregation of mutant p53 produces prion-like properties in cancer. Prion 2014, 8.
45. Rass K., Reichrath J. UV damage and DNA repair in malignant melanoma and nonmelanoma skin cancer. Adv. Exp. Med. Biol. 2008, 624:162-178.
46. Rivlin N., Brosh R., Oren M., Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer 2011, 2:466-474.
47. Rodust P.M., Stockfleth E., Ulrich C., Leverkus M., Eberle J. UV-induced squamous cell carcinoma-a role for antiapoptotic signalling pathways. Br. J. Dermatol. 2009, 161(Suppl. 3):107-115.
48. Sand M., Skrygan M., Georgas D., Sand D., Hahn S.A., Gambichler T., Altmeyer P., Bechara F.G. Microarray analysis of microRNA expression in cutaneous squamous cell carcinoma. J. Dermatol. Sci. 2012, 68:119-126.
49. Sand M., Skrygan M., Sand D., Georgas D., Hahn S.A., Gambichler T., Altmeyer P., Bechara F.G. Expression of microRNAs in basal cell carcinoma. Br. J. Dermatol. 2012, 167:847-855.
50. Sand M., Skrygan M., Sand D., Georgas D., Gambichler T., Hahn S.A., Altmeyer P., Bechara F.G. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi. Cell Tissue Res. 2013, 351:85-98.
51. Shen Z., Zhan G., Ye D., Ren Y., Cheng L., Wu Z., Guo J. MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin. Med. Oncol. 2012, 29:2473-2480.
52. Shi M., Liu D., Shen B., Guo N. Helpers of the cellular gatekeeper-miRNAs dance in P53 network. Biochim. Biophys. Acta 2010, 1805:218-225.
53. Sonnemann J., Marx C., Becker S., Wittig S., Palani C.D., Kramer O.H., Beck J.F. p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors. Br. J. Cancer 2014, 110:656-667.
54. Su X., Chakravarti D., Cho M.S., Liu L., Gi Y.J., Lin Y.L., Leung M.L., El-Naggar A., Creighton C.J., Suraokar M.B., Wistuba I., Flores E.R. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 2010, 467:986-990.
55. Suzuki H.I., Yamagata K., Sugimoto K., Iwamoto T., Kato S., Miyazono K. Modulation of microRNA processing by p53. Nature 2009, 460:529-533.
56. Thomson J.M., Newman M., Parker J.S., Morin-Kensicki E.M., Wright T., Hammond S.M. Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev. 2006, 20:2202-2207.
57. van Oijen M.G., Slootweg P.J. Gain-of-function mutations in the tumor suppressor gene p53. Clin. Cancer Res. 2000, 6:2138-2145.
58. Vaziri H., Dessain S.K., Ng Eaton E., Imai S.I., Frye R.A., Pandita T.K., Guarente L., Weinberg R.A. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001, 107:149-159.
59. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10:789-799.
60. Vousden K.H., Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2002, 2:594-604.
61. Wang Z., Sun Y. Targeting p53 for novel anticancer therapy. Trans. Oncol. 2010, 3:1-12.
62. Willis A., Jung E.J., Wakefield T., Chen X. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 2004, 23:2330-2338.
63. Wiman K.G. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy. Adv. Cancer Res. 2007, 97:321-338.
64. Xu J., Reumers J., Couceiro J.R., De Smet F., Gallardo R., Rudyak S., Cornelis A., Rozenski J., Zwolinska A., Marine J.C., Lambrechts D., Suh Y.A., Rousseau F., Schymkowitz J. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat. Chem. Biol. 2011, 7:285-295.
65. Yamakuchi M., Lowenstein C.J. MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle 2009, 8:712-715.
66. Yamakuchi M., Ferlito M., Lowenstein C.J. miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:13421-13426.
67. Yamamori T., DeRicco J., Naqvi A., Hoffman T.A., Mattagajasingh I., Kasuno K., Jung S.B., Kim C.S., Irani K. SIRT1 deacetylates APE1 and regulates cellular base excision repair. Nucleic Acids Res. 2010, 38:832-845.
68. Yi J., Luo J. SIRT1 and p53, effect on cancer, senescence and beyond. Biochim. Biophys. Acta 2010, 1804:1684-1689.
69. Zhao T., Li J., Chen A.F. MicroRNA-34a induces endothelial progenitor cell senescence and impedes its angiogenesis via suppressing silent information regulator 1. Am. J. Physiol. Endocrinol. Metab. 2010, 299:E110-E116.
70. Zhao X., Allison D., Condon B., Zhang F., Gheyi T., Zhang A., Ashok S., Russell M., MacEwan I., Qian Y., Jamison J.A., Luz J.G. The 2.5Å crystal structure of the SIRT1 catalytic domain bound to nicotinamide adenine dinucleotide (NAD+) and an indole (EX527 analogue) reveals a novel mechanism of histone deacetylase inhibition. J. Med. Chem. 2013, 56:963-969.
71. Ziegler A., Leffell D.J., Kunala S., Sharma H.W., Gailani M., Simon J.A., Halperin A.J., Baden H.P., Shapiro P.E., Bale A.E., et al. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:4216-4220.